BEAM Beam Therapeutics Inc.
High-Growth Software
F 30.0 / 100 pillar composite

AlphaQuality composite grade, weighted for high-growth software businesses.

⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.

Grade overrides the 30.0 pillar composite — hard gates always win.

Profitability

Weight: 15%
D- 30
  • 5yr Avg ROIC -12.4%
  • Operating Margin Trend +86.62 pp/yr

Capital Efficiency

Weight: 15%
F 0
  • 5yr Avg ROE -20.2%
  • 5yr Share-Count CAGR 11.4%

Growth Quality

Weight: 35%
B- 68
  • 5yr Revenue CAGR 28.1%
  • 5yr EPS CAGR 0.0%
  • Revenue-Growth Years (5) 4/5

Cash Generation

Weight: 20%
F 0
  • 5yr FCF Margin -225.7%
  • 5yr FCF/NI Conversion 0.00x

Balance Sheet

Weight: 10%
F 25
  • Net Debt / EBITDA 10.00x
  • Interest Coverage (EBIT/Int) -0.83x
  • Altman Z-Score 4.82

Stability

Weight: 5%
B+ 75
  • EPS Volatility (σ/μ) 0.00
  • Piotroski F-Score 3
  • Negative-Revenue Years (5) 1/5

Guru Flow

Curated superinvestor sentiment — not part of the AlphaQuality grade.
Holding

1 of 1 gurus held; 1 new buy; 1 full exit.

Holders
1
Avg Δ position
New buys
1
Full exits
1
As of Q1 2026